
Expanded offerings will increase Black representation in clinical trials, ensuring that new medicines are safe and effective for people of color.

Expanded offerings will increase Black representation in clinical trials, ensuring that new medicines are safe and effective for people of color.

Industry sees high increase in the use of QTLs.

Panel discussion at SCOPE highlights strategies to increase diversity in clinical trials.

Research shows there was no decline in non-COVID related study spending during height of pandemic.

ConneX will expand in key regions, including Japan, Central and Southern Europe, Scandinavia, and Southeast Asia.

New evidence-based reports offer analysis and actionable guidance to drug developers bringing new therapies to market.

Measuring different dimensions of diversity beforehand can lead to more thoughtful planning and execution.

Employee turnover continues to impact global market for talent.

Protocol provides an approach for compliance with Section V, Categories 4 and 5 of FDA's industry guidance.

Organizations to focus on development of children's clinical trials.

Webinar Date/Time: Tue, Mar 28, 2023 11:00 AM EDT

Sanjay Shukla, MD, MS, CEO of aTyr Pharma, discusses the company's clinical operations and ongoing Phase III study for pulmonary sarcoidosis.

Sunny Kumar, MD, partner at GSR Ventures speaks about reducing hospital readmissions for high-risk patients at the SCOPE 2023 conference in Orlando, FL.

Sunny Kumar, MD, partner at GSR Ventures speaks about venture capital in clinical research at the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education at CISCRP notes her key takeaways from the SCOPE 2023 conference in Orlando, FL.

Joan Chambers, senior director of marketing, communication & education for CISCRP names the three biggest challenges facing clinical trials at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA offers insights that small biopharma organizations can take away from larger companies at the SCOPE 2023 conference in Orlando, FL.

Hope Meely, chief clinical officer at Slope, offers a look into what she believes is the most important clinical trial development over the past five years.

Hope Meely, chief clinical officer at Slope, dives into what she envisions the clinical trial sector to develop in 2023.

Sunny Kumar, MD, partner at GSR Ventures speaks about how healthcare and clinical trials can work together to create a greater impact at the SCOPE 2023 conference in Orlando, FL.

Len Rosenberg, head of clinical operations at Beat AML, reveals how changing the backbone treatment to a different regimen is beneficial to the patient, in terms of the safety with the same efficacy.

Len Rosenberg, head of clinical operations at Beat AML, comments on how factors, such as proper data collection and reporting techniques, can prove to be efficient and help save lives.

Sunny Kumar, MD, partner at GSR Ventures speaks about areas of investment in clinical trials at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA speaks about the requirements of small biopharma clinical development at the SCOPE 2023 conference in Orlando, FL.

Murray L. Aitken, SVP of IQVIA speaks about how biopharma companies can take advantage of present opportunities at the SCOPE 2023 conference in Orlando, FL.

Alliance helps patients manage ePRO and wearables in one place.

PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions.

Partnership aims to unify solutions on single platform.

SCOPE session discusses key challenges of evaluating potential providers.